Biocon Limited (NSE:BIOCON) filed an intimation under Regulation 30 of the SEBI Listing Regulations on 3 August 2026, disclosing the commercial launch of Yesafili (aflibercept-jbvf) in the United States, an FDA-approved interchangeable biosimilar to Regeneron's Eylea 2 mg.
Key Highlights
- Yesafili (aflibercept-jbvf) was commercially launched in the United States on 3 August 2026, as disclosed in the Regulation 30 filing.
- The U.S. Food and Drug Administration had previously approved Yesafili and granted it interchangeable designation in May 2024, permitting pharmacy-level substitution in accordance with state laws.
- Yesafili is indicated for four ophthalmology conditions: neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
- U.S. sales of the reference product aflibercept reached approximately $5.89 billion in 2023, according to Regeneron's full-year 2023 financial results.
About the Company
Biocon Limited (NSE:BIOCON), headquartered in Bengaluru, India, is a global biopharmaceutical company operating in more than 120 countries. The company has commercialised 12 biosimilar products and 30-plus generic formulations globally, with seven manufacturing sites and three R&D facilities. Its therapy areas include diabetes, oncology, ophthalmology, immunology, and cardiovascular diseases.
Announcement in Detail
The filing, submitted by Company Secretary Rajesh U. Shanoy, confirms that Yesafili (aflibercept-jbvf) entered commercial availability in the United States on 3 August 2026. The product is a VEGF inhibitor biosimilar to Eylea 2 mg and carries interchangeable status from the FDA, meaning it may be substituted at the pharmacy level under applicable state laws. The vial formulation holds full interchangeable designation; the pre-filled syringe carries provisional interchangeability status.
Approval was based on a comprehensive analytical, nonclinical, and clinical data package. A Phase 3 INSIGHT Study comparing Yesafili with Eylea 2 mg in diabetic macular edema patients showed no clinically meaningful differences in pharmacokinetics, safety, efficacy, or immunogenicity, as stated in the press release enclosed with the filing.
Impact on Investors
The filing shows that Yesafili now competes directly in the U.S. ophthalmology biosimilars market, where annual aflibercept sales were reported at approximately $5.89 billion in 2023. Investors will note that the interchangeable designation is commercially significant, as it allows pharmacy-level substitution without a new physician prescription, which can support volume uptake relative to non-interchangeable biosimilars.
Shareholders will observe that Yesafili is a trademark of Biocon Biologics Limited, a subsidiary. The filing does not disclose pricing, contracted payer agreements, or revenue projections, so the financial contribution to Biocon's consolidated results cannot be quantified from this announcement alone.
Sector / Market Context
The U.S. biosimilars market has expanded materially since the Biologics Price Competition and Innovation Act established the regulatory pathway for interchangeable biosimilars. The FDA's interchangeable designation for ophthalmic VEGF inhibitors is relatively recent, and an estimated 19.8 million Americans aged 40 and older were living with age-related macular degeneration as of 2019, according to data cited by the CDC's Vision and Eye Health Surveillance System.